Pfizer Inc. (FRA:PFEB)
Germany · Delayed Price · Currency is EUR | Market Cap | 149.22B +17.6% |
| Revenue (ttm) | 55.83B +1.3% |
| Net Income | 3.54B -59.0% |
| EPS | 0.16 -59.3% |
| Shares Out | n/a |
| PE Ratio | 49.63 |
| Forward PE | 9.93 |
| Dividend | 0.48 (6.06%) |
| Ex-Dividend Date | Nov 6, 2026 |
| Volume | n/a |
| Open | 7.90 |
| Previous Close | 8.05 |
| Day's Range | 7.90 - 7.90 |
| 52-Week Range | 5.80 - 8.50 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Nov 3, 2026 |
About Pfizer
Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States and internationally. It operates in three segments: Biopharma, PC1, and Pfizer Ignite. The company offers internal medicine products, including cardiovascular metabolic diseases products under the Eliquis brand; migraine products under the Nurtec ODT/Vydura and Zavzpret brand; vaccines under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and Paxlovid for the treatment of COVID-19. It als... [Read more]
Financial Performance
In 2025, Pfizer's revenue was $62.58 billion, a decrease of -1.65% compared to the previous year's $63.63 billion. Earnings were $7.77 billion, a decrease of -3.24%.
Financial numbers in USD Financial StatementsNews
Why Pfizer Is Tapping Private Equity to Back Its Once-Monthly Weight-Loss Drug
Blackstone Life Sciences agrees to pay $1.5 billion in development costs for Pfizer's berobenatide through 2028 in exchange for milestone-based payments.
Pfizer now sees 2026 adjusted EPS $1.45-$1.54, consensus $2.00
Now sees 2026 revenue $1.76B-$1.77B, consensus $1.81B.
Pfizer Slides: Investor presentation
Pfizer has posted slides in relation to its latest quarterly earnings report, which was published on November 12, 2026.
Pfizer Signs $1.5 Billion Deal With Blackstone to Fund Weight-Loss-Drug Development
The investment is set to cover development costs for berobenatide, an investigational drug being studied for chronic weight management and obesity-related conditions.
Pfizer secures up to $1.5 billion from Blackstone for obesity drug development
Pfizer said on Wednesday that Blackstone would provide up to $1.5 billion through 2028 to help fund the development of an experimental monthly obesity treatment the drugmaker picked up last year wit...
Pfizer, Blackstone Life Sciences announce strategic co-funding agreement
Pfizer (PFE) and Blackstone Life Sciences (BX) announced a strategic co-funding agreement under which funds managed by Blackstone will pay up to a total of $1.5 billion of development costs…
Pfizer and Blackstone Life Sciences Announce Strategic Funding Agreement for Obesity Program
NEW YORK & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) and Blackstone Life Sciences (“Blackstone”) today announced a strategic co-funding agreement under which funds managed by Blacksto...
Pfizer Invites Public to View and Listen to Webcast of Pfizer Discussion at Healthcare Conference
NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) invites investors and the general public to view and listen to a webcast of a discussion with Albert Bourla, Chairman and Chief Executive Officer, at...
Pfizer price target raised to $34 from $33 at Freedom Broker
Freedom Broker raised the firm’s price target on Pfizer (PFE) to $34 from $33 and keeps a Buy rating on the shares. Q3 results were “strong,” with revenue and EPS…
Pfizer downgraded to Hold from Buy at DZ Bank
DZ Bank downgraded Pfizer (PFE) to Hold from Buy with a $33 price target
Pfizer price target raised to $33 from $31 at Guggenheim
Guggenheim analyst Vamil Divan raised the firm’s price target on Pfizer (PFE) to $33 from $31 and keeps a Buy rating on the shares.
Pfizer (PFE) Stock Looks Attractive for Income Investors
Pfizer ($PFE) stock looks attractive for income investors because of its well-covered dividend and modest valuation. The drug maker’s shares have outperformed the S&P 500 (SPX) in 2026, mirroring the…
Pfizer price target raised to $35 from $33 at Scotiabank
Scotiabank analyst Louise Chen raised the firm’s price target on Pfizer (PFE) to $35 from $33 and keeps an Outperform rating on the shares. The firm believes the earnings potential…
Pfizer price target lowered to $26 from $28 at Morgan Stanley
Morgan Stanley lowered the firm’s price target on Pfizer (PFE) to $26 from $28 and keeps an Equal Weight rating on the shares.
Pfizer price target raised to $28 from $25 at RBC Capital
RBC Capital raised the firm’s price target on Pfizer (PFE) to $28 from $25 and keeps a Sector Perform rating on the shares after its Q3 earnings beat and guidance…
Pfizer price target raised to $30 from $27 at UBS
UBS analyst Michael Yee raised the firm’s price target on Pfizer (PFE) to $30 from $27 and keeps a Neutral rating on the shares.
United Therapeutics announces buydown of Ralinepag royalty
United Therapeutics (UTHR) announced that it has entered into an amendment with Arena Pharmaceuticals, a subsidiary of Pfizer (PFE), which eliminates all royalty obligations under its exclusive licens...
Pfizer price target raised to $30 from $27 at Citi
Citi raised the firm’s price target on Pfizer (PFE) to $30 from $27 and keeps a Neutral rating on the shares. The firm views the company’s Q3 report as showing…
Pfizer CEO Albert Bourla on Q3 earnings, patent expirations, obesity drug market
CNBC's Annika Kim Constantino and Albert Bourla, Pfizer CEO, join 'The Exchange' to discuss Pfizer's Q3 earnings, patent expirations, and more.
Midday Fly By: Apple warns of lower margins, Pfizer reports ‘beat and raise’
The major averages were mixed near noon, with the Dow fractionally lower but the S&P 500 and Nasdaq higher, as investors digest the latest spate of corporate earnings reports. Apple…
Pfizer Earnings Call Transcript: Q3 2026
Q3 revenue reached $16.6B, with non-COVID products up 7% operationally and launched/acquired products up 32%. FY26 revenue and adjusted EPS guidance rose; LOEs, pricing and pipeline execution remain key drivers and risks.
Pfizer Slides: Q3 2026
Pfizer has posted slides in relation to its Q3 2026 quarterly earnings report, which was published on November 3, 2026.
Pfizer Earnings release: Q3 2026
Pfizer released its Q3 2026 earnings on November 3, 2026, summarizing the period's financial results.
Pfizer Prepared remarks: Q3 2026
Pfizer filed a regulatory document on November 3, 2026 disclosing important business information.
Pfizer Quarterly report: Q3 2026
Pfizer has published its Q3 2026 quarterly earnings report on November 3, 2026.